Compare Novo Nordisk A/S (NVO) vs Utilities Select Sector SPDR Fund (XLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Utilities Select Sector SPDR Fund — how do they compare? Novo Nordisk A/S trades at $45.08 (market cap $198.57B), while Utilities Select Sector SPDR Fund trades at $43.21. The key difference: Novo Nordisk A/S pays a 4.03% dividend while Utilities Select Sector SPDR Fund pays none, and Novo Nordisk A/S is trading nearer its 52-week high, Utilities Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| NVO | XLU | |
|---|---|---|
Market Cap | $198.57B | — |
Sector | Health | — |
52-Week High | $63.98 | $47.73 |
52-Week Low | $35.29 | $41.86 |
Enterprise Value | $213.37B | — |
Dividend Yield | 4.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
XLU trades at $43.45, up 0.86% with a bullish technical signal despite bearish moving averages. The utilities ETF shows neutral oscillators with RSI at 57.53, trading near key support at $43. Recent news highlights XLU's defensive positioning amid market volatility and AI power demand growth, though some analysts question its AI exposure concentration.
Outlook remains cautiously optimistic as utilities benefit from AI-driven power demand and defensive characteristics during economic uncertainty. Key risks include regulatory changes affecting data-center growth and interest rate sensitivity. The sector's stable dividend profile provides income support while growth potential depends on AI infrastructure expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Utilities Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →
